Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. Sep 15, 2023; 15(9): 1626-1635
Published online Sep 15, 2023. doi: 10.4251/wjgo.v15.i9.1626
Table 1 Clinicopathological characteristics of 147 metastatic gastric cancer patients
Features
Frequency, n (%)
Gender
    Female37 (25.2)
    Male110 (74.8)
ECOG PS
    032 (21.8)
    183 (56.5)
    232 (21.8)
Comorbidity
    No74 (50.3)
    Yes73 (49.7)
Smoking
    No69 (46.9)
    Yes78 (53.1)
Surgery
    No90 (61.2)
    Yes57 (38.8)
Type of surgery
    No90 (61.2)
    Total gastrectomy41 (27.9)
    Subtotal gstrectomy16 (10.9)
Patology
    Adenocarcinom128 (87.1)
    Signet ring cell carcinom15 (10.2)
    Musinoz adenocarcinom2 (1.4)
    Mix carcinom2 (1.4)
Diferantiation
    Well5 (3.4)
    Moderate 74 (50.3)
    Poorly 53 (36.1)
    Signet ring cell carcinoma15 (10.2)
Surgical margin
    No operation90 (61.2)
    Positive6 (4.1)
    Negative51 (34.7)
Tumor location
    Fundus, cardia48 (32.7)
    Korpus 56 (38.1)
    Antrum, pylor43 (29.3)
De novo metastasis
    No 44 (29.9)
    Yes103 (70.1)
Age group
    ≤ 63 74 (50.3)
    > 6373 (49.7)
Table 2 Distribution of patients according to hemoglobin, albumin, lymphocyte, and platelet score in subgroups
Features
HALP low, n (%)
HALP high, n (%)
P value
Gender0.816
    Female23 (25.8)14 (24.2)
    Male66 (74.2)44 (75.9)
ECOG PS0.02
    016 (18)16 (27.6)
    147 (52.8)36 (62.1)
    226 (29.2)6 (10.3)
Comorbidity0.008
    No37 (41.6)37 (63.8)
    Yes52 (58.4)21 (36.2)
Smoking0.679
    No43 (48.3)26 (44.8)
    Yes46 (51.7)32 (55.2)
Surgery0.804
    No56 (62.9)34 (58.6)
    Yes33 (37.1)24 (41.4)
Type of surgery0.783
    No55 (61.8)34 (58.6)
    Total gastrectomy23 (25.8)18 (31)
    Subtotal gastrectomy10 (11.2)6 (10.3)
Patology0.18
    Adenocarcinom79 (88.8)49 (84.5)
    Signet ring cell carcinom8 (9)7 (12.1)
    Musinoz adenocarcinom2 (2.2)0 (0)
    Mix carcinom0 (0)2 (3.4)
Diferantiation0.045
    Well1 (1.1)4 (6.9)
    Moderate 42 (47.2)32 (55.2)
    Poorly 38 (42.7)14 (24.1)
    Signet ring cell carcinoma8 (9)8 (13.8)
Tumor location0.142
    Fundus, cardia25 (28.1)23 (39.7)
    Corpus33 (37.1)23 (39.7)
    Antrum, pylor31 (34.8)12 (20.7)
De novo metastasis0.894
    No27 (30.3)17 (29.3)
    Yes62 (69.7)41 (70.7)
Table 3 Analysis of prognostic factors in terms of overall survival
FeaturesMedian (months)Univariate analysis
Multivariate analysis
HR (95%CI)
P value
HR (95%CI)
P value
HALP groups
    HALP low7.50.59 (0.41-0.85)0.004Reference0.001
    HALP high10.40.53 (0.36-0.78)
NLR groups
    NLR low9.11.10 (0.78-1.56)0.582
    NLR high8.0
PLR groups
    PLR low8.61.18 (0.83-1.68)0.350
    PLR high8.4
Age groups
    ≤ 6310.21.96 (1.37-2.8)0.000Reference0.060
    > 636.91.47 (0.98-2.19)
ECOG PS
    0-19.11.57 (1.04-2.36)0.030Reference0.850
    26.91.04 (0.66-1.64)
Comorbidity
    No10.21.67 (1.18-2.36)0.004Reference0.303
    Yes6.21.22 (0.84-1.78)
Diferantiation
    Well-moderate8.61.10 (0.78-1.53)0.600
    Poorly-Signet ring cell8.4
Second line CT
    No4.90.24 (0.16-0.35)0.000Reference< 0.001
    Yes15.40.23 (0.16-0.34)
De novo metastasis
    No9.20.94 (0.65-1.37)0.754
    Yes8.2
Gender
    Female9.11.53 (1.03-2.28)0.035Reference0.051
    Male8.21.52 (0.99-2.31)
Tumor location
    Fundus, cardia7.50.056
    Corpus8.8--
    Antrum, pylor9.2